Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452540 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis
A Phase 2 study, sponsored by Afimmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03452540: Clinical Trial Phase 2 study, sponsored by Afimmune.
NCT03452540 is a Phase 2 study that was terminated before completion, run by Afimmune. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03452540, a Phase 2 study, was terminated before completion, sponsored by Afimmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this randomised, double-blind, placebo-controlled, phase II study is to assess the efficacy and safety of orally administered DS102 in adult patients with acute decompensated alcoholic hepatitis
Primary Outcome
To evaluate the safety of orally administered DS102 in the treatment of adult patients with severe acute decompensated AH.
Interventions
- DRUG 1000mg DS102 (BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 2 |
Why NCT03452540 stopped before completion
NCT03452540 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which 1000mg DS102 (BID) is the first listed.
NCT03452540 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03452540 about?
NCT03452540 is a clinical study titled "Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis". The purpose of this randomised, double-blind, placebo-controlled, phase II study is to assess the efficacy and safety of orally administered DS102 in adult patients with acute decompensated alcoholic hepatitis
What is the current status of trial NCT03452540?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2018-11-28. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT03452540?
The interventions under investigation include: 1000mg DS102 (BID) (DRUG).
Who is sponsoring clinical trial NCT03452540?
This trial is sponsored by Afimmune, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03452540's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI